Terapeutica combinada de interferones con ribavirinacomparación de efectividad y perfil de efectos adversos

Laburpena

TITULO: TERAPÉUTICA COMBINADA DE INTERFERONES CON RIBAVIRINA: COMPARACIÓN DE EFECTIVIDAD Y PERFIL DE EFECTOS ADVERSOS RESUMEN: Prospective-retrospective study, during a 4-year period, of chronic hepatitis C patients treated with peginterferon alfa-2a plus ribavirin or peginterferon alfa-2b plus ribavirin combined therapy. The patients were attended at a hospital pharmacy out-patient unit. The aim was to establish and compare the effectiveness and adverse effects of these two different combined therapies. To these currently applied treatments against the hepatitis C virus in the daily clinical practice was added the involvement of a pharmacist as part of a multidisciplinary support team to improve the treatment adherence. Neither effectiveness nor adverse effects showed a significative difference (p > 0.05) between both therapeutical alternatives. However a higher Sustained viral Response was obtained in both cases compared to those obtained in the clinical trials published until now, mainly due to a higher patience's adherence to therapy. Along the same une, the voluntary drop-out rate for both alternatives was 1.3% compared to the 4.4% published. "The use of technical means that included graphics and illustrations about the treatment and the patient's information guide called "Saber +", as complementary to the direct patient information and education method, in the context of pharmaceutical care, were considered important tools to improve the adherence to the therapy. Finally, any strategy implemented with the aim to achieve full patient's adherence to the treatment against hepatitis C virus, will imply a direct improvement for the patient, in terms of morbidity and mortality and quality of live and for the public health systems, in terms of efficiency.